Information de reference pour ce titreAccession Number: | 00000816-199910000-00013.
|
Author: | Lopez, Oscar L. MD; Wisniewski, Stephen R. PhD; Becker, James T. PhD; Boller, Francois MD, PhD; DeKosky, Steven T. MD
|
Institution: | From the Alzheimer's Disease Research Center (Drs Lopez, Becker, and DeKosky) and the Departments of Neurology (Drs Lopez, Becker, and DeKosky), Psychiatry (Drs Becker and DeKosky), and Epidemiology (Dr Wisniewski), University of Pittsburgh, Pittsburgh, Pa; and the Centre Paul Broca, Paris, France (Dr Boller).
|
Title: | Psychiatric Medication and Abnormal Behavior as Predictors of Progression in Probable Alzheimer Disease.[Article]
|
Source: | Archives of Neurology. 56(10):1266-1272, October 1999.
|
Abstract: | Objective: To examine whether the use of psychiatric medication and the presence of abnormal behaviors affects the progression of Alzheimer disease.
Design: Cross-sectional with longitudinal follow-up and the likelihood of arriving at 4 end points: (1) Mini-Mental State Examination score of 9 or lower; (2) Blessed Dementia Rating Scale score of 15 or higher for activities of daily living; (3) nursing home admission; and (4) death, evaluated using a proportional hazard model with 9 variables: psychosis, insomnia, wandering, aggression, psychomotor agitation, depression, and use of antidepressants, antipsychotic agents, or sedatives/hypnotics.
Setting: Multidisciplinary dementia research clinic.
Patients: We examined baseline and follow-up behavioral symptoms and the use of psychiatric medication in 179 mildly to moderately impaired patients with probable Alzheimer disease participating in a longitudinal study of dementia. Patients were observed from 2.4 to 172 months (mean duration+/-SD, 49.5+/-27.4 months).
Results: Nine patients (5%) were taking sedatives/hypnotics; 16 (9%), antipsychotic agents; and 22 (12%), antidepressants at study entry. Patients taking antipsychotic agents had lower Mini-Mental State Examination scores and higher Blessed Dementia Rating Scale scores for activities of daily living than patients not taking any medication. Using proportional hazard analysis with time-dependent covariates for individual psychiatric symptoms and medications, we found that the development of psychosis was associated with functional decline (time to Blessed Dementia Rating Scale score of >=15), institutionalization, aggression, and agitation with functional decline after adjusting for age at study entry, education, Mini-Mental State Examination scores, and Blessed Dementia Rating Scale scores. Use of antipsychotic medication was associated with functional decline, and sedatives/hypnotics with death. Neither the presence of psychiatric symptoms nor use of medication was associated with rate of cognitive decline (time to Mini-Mental State Examination score of <=9).
Conclusions: These findings indicate that the use of antipsychotic agents and sedatives can affect the natural course of Alzheimer disease. Psychosis, agitation, and aggression are important predictors of outcome, even when the effects of medication to treat them is taken into account.
Arch Neurol.1999;56:1266-1272
Copyright 1999 by the American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. American Medical Association, 515 N. State St, Chicago, IL 60610.
|
Author Keywords: | Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; Disease Progression; Hypnotics and Sedatives.
|
References: | 1. Becker JT, Boller F, Lopez OL, Saxton J, McGonigle K. The natural history of Alzheimer disease: description of study cohort and accuracy of diagnosis. Arch Neurol. 1994;51:585-594.
2. Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54:257-263.
3. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry. 1989;146:577-587.
4. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989;25:39-48.
5. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology. 1994;44:2300-2307.
6. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer disease. Arch Neurol. 1994;51:676-681.
7. Lopez OL, Brenner RP, Becker JT, Ulrich RF, Boller F, DeKosky ST. EEG spectral abnormalities and psychosis as predictors of cognitive and functional decline in probable Alzheimer's disease. Neurology. 1997;48:1521-1525.
8. Walsh JS, Welch HG, Larson EB. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med. 1990;113:429-434.
9. Moritz DJ, Fox PJ, Luscombe FA, Kraemer HC. Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol. 1997;54:878-885.
10. Lopez OL, Boller F, Becker JT, Miller M, Reynolds CF. Alzheimer's disease and depression: neuropsychological impairment and progression of the illness. Am J Psychiatry. 1990;147:855-860.
11. Burns A, Lewis G, Jacoby R, Levy R. Factors affecting survival in Alzheimer's disease. Psychol Med. 1991;21:363-370.
12. Jagger C, Clarke M, Stone A. Predictors of survival with Alzheimer's disease: a community-based study. Psychol Med. 1995;25:171-177.
13. Wragg RE, Jeste DV. Neuroleptics and alternative treatments. Management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions. Psychiatr Clin North Am. 1988;11:195-213.
14. Semla TP, Cohen D, Freels S, et al. Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease. Pharmacotherapy. 1995;15:495-501.
15. Devanand DP, Sackheim HA, Brown RP, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer disease. Arch Neurol. 1989;46:854-857.
16. Devanand DP. Behavioral complications and their treatment in Alzheimer's disease. Geriatrics. 1997;52(suppl 2):S37-S39.
17. Burke WJ, Dewan V, Wengel SP, Roccaforte WH, Nadolny GC, Folks DG. The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia. Int J Geriatr Psychiatry. 1997;12:519-525.
18. Lemke MR. Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. J Clin Psychiatry. 1995;56:354-357.
19. Stern RG, Dyffelmeyer ME, Zemishlani Z, Davidson M. The use of benzodiazepines in the management of behavioral symptoms in demented patients. Psychiatr Clin North Am. 1991;14:375-384.
20. Randels PM, Marco LA, Hanspal NS, Robinson B. Possible lithium-induced extrapyramidal effects in Alzheimer's disease. Hillside J Clin Psychiatry. 1984;6:117-121.
21. Goad DL, Davis CM, Liem P, Fuselier CC, McCormack JR, Olsen KM. The use of selegiline in Alzheimer's patients with behavioral problems. J Clin Psychiatry. 1991;52:342-345.
22. Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry. 1990;51:115-118.
23. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54-61.
24. Porsteinsson AP, Tariot PN, Erb R, Gaile S. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry. 1997;5:344-351.
25. Weiler PG, Mungas D, Bernick C. Propanolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol. 1988;1:226-230.
26. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicenter study. Br J Psychiatry. 1990;157:894-901.
27. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment of dementia. J Am Geriatr Soc. 1990;38:553-563.
28. Schneider LS, Sobin PB. Non-neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: a selective review. Int J Geriatr Psychiatry. 1991;6:691-708.
29. McKhann G, Drachman DA, Folstein MF, Katzman R, Price DL, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
30. Hachinski VC, Iliff LD, Zihka E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632-637.
31. Mezzich JE, Dow JT, Cottman GA. Developing an information system for a comprehensive psychiatric institute, I: principles, design, and organization. Behav Res Methods Instrument. 1981;13:459-463.
32. Lopez OL, Gonzalez MP, Becker JT, Reynolds CF, Sudilovsky A, DeKosky ST. Symptoms of depression and psychosis in Alzheimer's disease and frontotemporal dementia. Neuropsychiatry Neuropsychol Behav Neurol. 1996;9:154-161.
33. Kaufer DA, Cummings JL, Christine D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci. 1998;10:55-63.
34. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and senile changes in the cerebral white matter of elderly subjects. Br J Psychiatry. 1968;114:797-811.
35. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. Psychiatry Res. 1975;12:189-198.
36. Devanand DP, Jacobs DM, Tang M, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54:257-263.
37. Teri L, Larson EB, Reifler BV. Behavioral disturbance in dementia of the Alzheimer's type. J Am Geriatr Soc. 1988;36:1-6.
38. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
39. Hoehn M, Yahr M. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427-442.
40. Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry. 1996;153:1438-1443.
41. Mendez MF, Martin RJ, Smyth KA, Whitehouse PJ. Psychiatric symptoms associated with Alzheimer's disease. J Neuropsychiat Clin Neurosci. 1990;2:28-33.
42. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease, IV: disorders of behavior. Br J Psychiatry. 1990;157:86-94.
43. Burns A, Jacoby R, Levy R. Psychiatric penomena in Alzheimer's disease, I: disorders of thought content. Br J Psychiatry. 1990;157:72-76.
44. Lopez OL, Becker JT, Brenner RP, Rosen J, Bajulaiye OI, Reynolds CF. Alzheimer's disease with delusions and hallucinations: neuropsychological and electroencephalographic correlates. Neurology. 1991;41:906-912.
45. Mortimer JA, Ebbitt B, Jun SP, Finch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology. 1992;42:1689-1696.
46. Rovner BW. Depression and increased risk of mortality in the nursing home patient. Am J Med. 1993;94(suppl):19S-22S.
47. Hamel M, Gold DP, Andres D, et al. Predictors and consequences of aggressive behavior by community-based dementia patients. Gerontologist. 1990;30:206-211.
48. Ryden MB. Aggressive behavior in persons with dementia who live in the community. Alzheimer Dis Assoc Disord. 1988;2:342-355.
49. Lieberman MA, Kramer JH. Factors affecting decisions to institutionalize demented elderly. Gerontologist. 1991;31:371-374.
50. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990;147:1049-1051.
51. Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 1989;146:45-49.
52. Reynolds CF, Perel JM, Kupfer DJ, Zimmer B, Stack JA, Hoch CC. Open-trial response to antidepressant treatment in elderly patients with mixed depression and cognitive impairment. Psychiatry Res. 1987;21:111-122.
53. Teri L, Reifler BV, Veith RC, et al. Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J Gerontol. 1991;46:P372-P377.
54. Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics. 1997;38:246-252.
55. Devanand DP, Levy SR. Neuroleptic treatment of agitation and psychosis in dementia. J Geriatr Psychiatry Neurol. 1995;8(suppl 1):S18-S27.
56. King DJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry. 1990;157:799-811.
57. Curran HV, Bond A, O'Sullivan G, Bruce M, Marks I. Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. Psychol Med. 1994;24:969-976.
58. Ray WA. Psychotropic drugs and injuries among the elderly: a review. J Clin Psychopharmacol. 1992;12:386-396.
59. Robin DW, Hasan SS, Edeki T, Lichtenstein MJ, Shiavi RG, Wood AJ. Increased baseline sway contributes to increased losses of balance in older people following triazolam. J Am Geriatr Soc. 1996;44:300-304.
60. Wysowski DK, Baum C, Ferguson WJ, Lundin F, Ng MJ, Hammerstrom T. Sedative-hypnotic drugs and the risk of hip fracture. J Clin Epidemiol. 1996;49:111-113.
61. Borson S, Raskind MA. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology. 1997;48(5 suppl 6):S17-S24.
62. Aarsland D, Cummings JL, Yenner G, Miller B. Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Am J Psychiatry. 1996;153:243-247.
63. Deutsch LH, Bylsma FW, Rovner BW, Steele C, Folstein MF. Psychosis and physical aggression in probable Alzheimer's disease. Am J Psychiatry. 1991;148:1159-1163.
|
Language: | English.
|
Document Type: | Original Contribution.
|
Journal Subset: | Clinical Medicine. Behavioral & Social Sciences.
|
ISSN: | 0003-9942
|
NLM Journal Code: | 80k, 0372436
|
Annotation(s) | |
|
|